WorkBoat Header Background Image

WorkBoat+ Membership – Free to Join

The 2026 WorkBoat Diesel Directory is here. See engine specs and manufacturer listings for the U.S. commercial fleet. → Download Free

Workboat Indexes

Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Workboat Indexes
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nektar Therapeutics - Common Stock (NQ:NKTR)

67.00 -1.30 (-1.90%)
Streaming Delayed Price Updated: 9:31 AM EDT, Jul 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nektar Therapeutics - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Assessing Nektar Therapeutics: Insights From 4 Financial Analysts ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 12, 2025 ↗
 
Via Benzinga
News headline image
Sweet Nektar? ↗
NKTR has had a terrible time of it for years, but maybe it’s finally ready to turn around. 
Via Talk Markets
News headline image
Nektar Therapeutics Earnings Preview ↗
 
Via Benzinga
News headline image
Recap: Nektar Therapeutics Q3 Earnings ↗
 
Via Benzinga
News headline image
Top movers in Friday's after hours session ↗
As the regular session of the US market concludes on Friday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
 
Via Benzinga
News headline image
Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential ↗
Piper Sandler initiates coverage of Nektar Therapeutics, citing REZPEG's Treg-focused action as a potential breakthrough for Alopecia areata treatment. 
Via Benzinga
News headline image
A Preview Of Nektar Therapeutics's Earnings ↗
 
Via Benzinga
News headline image
Expert Ratings for Nektar Therapeutics ↗
 
Via Benzinga
News headline image
Nektar Therapeutics: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
NKTR Stock Earnings: Nektar Therapeutics Misses EPS, Beats Revenue for Q2 2024 ↗
NKTR stock results show that Nektar Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
NKTR Stock Earnings: Nektar Therapeutics Meets EPS, Beats Revenue for Q1 2024 ↗
NKTR stock results show that Nektar Therapeutics met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Biotech's Lawsuit With Eli Lilly Might Catalyze Stock ↗
Nektar Therapeutics commenced a Phase 2b clinical trial evaluating its lead product candidate rezpegaldesleukin, in patients with severe to very severe alopecia areata, a disease-causing patchy hair... 
Via Talk Markets
Topics Lawsuit
News headline image
Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Shares of Bitdeer Technologies Group (NASDAQ: BTDR) rose sharply during Monday’s session after the company reported preliminary fourth-quarter financial results, announced the successful testing of its... 
Via Benzinga
News headline image
Earnings Scheduled For March 4, 2024 ↗
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is estimated to report earnings for its fourth quarter. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
The One-Minute Market Report - Saturday, Aug. 12 ↗
In this weekly outlook, I examine the asset classes, sectors, and ETFs that led the market higher, and which market segments bucked the trend by moving lower. Signs that market participation is... 
Via Talk Markets
Topics ETFs
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers Vistagen Therapeutics, Inc. (NASDAQ: VTGN) shares jumped 747.6% to $14.24 after the company announced its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of... 
Via Benzinga
News headline image
Why Is Nektar Therapeutics Stock Surging Today? ↗
Nektar Therapeutics Inc (NASDAQ: NKTR) said its former partner Eli Lilly And Co (NYSE: LLY) had presented "erroneous data" from two Phase 1b studies of its atopic dermatitis drug,  
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2023 ↗
 
Via Benzinga
News headline image
Tempur Sealy International To Rally Around 32%? Here Are 10 Other Analyst Forecasts For Wednesday ↗
Keybanc raised the price target for Tempur Sealy International, Inc. (NYSE: TPX) from $48 to $50. Keybanc analyst Bradley Thomas maintained an Overweight rating. Tempur Sealy International shares rose... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Privacy Policy DSAR Requests Terms of Use Locations Events, Products & Services
© 2026 Diversified Communications. All rights reserved.